This Information Is Intended for US Healthcare Professionals Now you can help patients living with severe axillary hyperhidrosis that is inadequately managed with topical agents. PROVEN EFFICACY 55% of BOTOX® patients achieved primary statistical study endpoint (P <.001 vs 6% placebo)1 LASTING DURATION 201-day median duration of response1 COMPELLING RESULTS 81% of BOTOX® patients achieved at least a 50% reduction in axillary sweating measured gravimetrically at 4 weeks post-injection (P<.001 vs 41% placebo) (95% CI)2 (clinical significance unknown) HYPERHIDROSIS DISEASE SEVERITY SCALE (HDSS) A 4-point scale for categorizing the severity of primary axillary hyperhidrosis3
REFERENCE
  1. BOTOX® Prescribing Information.
  2. Data on file. Allergan, Inc.; Pivotal clinical trial, Study 016.
  3. Data on file, Allergan, Inc.; Pivotal clinical trials, Study 505 and Study 506
LEARN MORE